Industry News — Clinical Updates

Novartis Introduces Lucentis Pre-Filled Syringe

Novartis (Basel, Switzerland) has announced the launch of the Lucentis (ranibizumab) intraocular pre-filled syringe (PFS) in Germany. Novartis received European regulatory approval for the PFS in October 2013.

The Lucentis PFS is designed to reduce the risk of adverse events and enhance the treatment process. It offers the potential for improved patient safety by reducing nonsterile preparatory steps and includes safety features, such as a nonretractable plunger. The PFS design features, such as a smaller syringe barrel, also provide greater dosage accuracy.

Novartis plans to introduce the Lucentis PFS to additional markets in 2014.

Updated: March 21, 2014